Caffeine Interactions

Combining caffeine with ephedra can cause dangerous increases in heart rate and blood pressure.

Caffeine and theophylline are closely related methylxanthines that share the CYP1A2 metabolic pathway and compete for the same adenosine receptors. Concurrent use can raise theophylline levels and add pharmacodynamically to cause tachycardia, tremor, nausea, seizures or arrhythmias.

Caffeine inhibits CYP1A2, the main enzyme that metabolizes clozapine. High caffeine intake (especially energy drinks) can dramatically raise clozapine levels, with case reports of life-threatening toxicity including multiorgan failure.

Caffeine and yohimbine are both potent stimulants. Yohimbine blocks alpha-2 adrenergic receptors, raising norepinephrine, while caffeine blocks adenosine receptors and amplifies sympathetic output. Combined, they can cause large rises in heart rate and blood pressure, severe anxiety, tremor, panic attacks, arrhythmias, and have been linked to hospital visits and rare cardiovascular events.

Caffeine (coffee, tea) can reduce iron absorption by up to 60%.

Excessive caffeine increases calcium excretion in urine.

Caffeine counteracts melatonin and can delay sleep onset.

Caffeine increases renal clearance of lithium by promoting natriuresis and increasing glomerular filtration, so chronic caffeine intake lowers lithium blood levels. A sudden reduction in caffeine intake can raise serum lithium into the toxic range, while abruptly increasing caffeine can lower levels and worsen mood symptoms.

Ethinyl estradiol in oral contraceptives inhibits CYP1A2, the enzyme that metabolizes caffeine. This roughly doubles caffeine's area-under-the-curve and prolongs its half-life, intensifying jitteriness, insomnia and palpitations.

Ciprofloxacin is a potent CYP1A2 inhibitor. Co-administration increases caffeine's area-under-the-curve by 50-100% and prolongs its half-life, producing exaggerated central nervous system and cardiovascular stimulation.

Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, the enzyme that performs about 95% of caffeine demethylation, raising caffeine clearance by 40-65% and shortening its half-life from roughly 6 hours to 3.5 hours in smokers. Quitting smoking can cause caffeine levels to rise sharply, contributing to jitters, anxiety, palpitations, and insomnia.

Caffeine and amphetamine salts are both sympathomimetic stimulants. Combining them raises heart rate and blood pressure, worsens anxiety and insomnia, and increases the risk of palpitations, arrhythmias and panic attacks.

Sertraline and caffeine can each contribute to anxiety, insomnia, tremor and GI upset, and sertraline may modestly slow caffeine clearance via CYP1A2 inhibition. The pharmacokinetic effect is small but the additive symptomatic effect can be uncomfortable.

Early studies suggested caffeine blunts the ergogenic effect of creatine on muscle phosphocreatine resynthesis and high-intensity performance, but subsequent randomized trials show the combination is generally additive or neutral; the original blunting effect appears specific to chronic co-ingestion during creatine loading rather than acute pre-workout use.

Caffeine raises systemic vascular resistance and heart rate, partially opposing propranolol's blood-pressure and heart-rate lowering effects. High caffeine intake can also worsen tremor and anxiety that propranolol is prescribed to treat.

In vitro and observational studies suggest high caffeine intake (>300 mg/day) may decrease vitamin D receptor (VDR) protein expression in osteoblasts and is associated with lower serum 25-hydroxyvitamin D levels in some NHANES data. The clinical effect is modest and most relevant for bone health in postmenopausal women with low calcium intake.

Panax ginseng has its own mild stimulant and sympathomimetic activity that adds to caffeine's effects on heart rate, blood pressure, and CNS arousal. The combination can produce jitteriness, insomnia, palpitations, anxiety, and elevated blood pressure, with greater risk in people with hypertension, arrhythmia, or anxiety disorders.

Ashwagandha is an adaptogen that lowers cortisol and reduces perceived anxiety; caffeine is a stimulant that raises cortisol and can increase anxiety. Taking them together can blunt caffeine's anxiety and jitter side effects while preserving its alertness benefit, but ashwagandha may also slightly dampen caffeine's peak stimulant effect.

L-theanine, an amino acid from tea, smooths out caffeine's stimulant effects by promoting alpha-wave brain activity associated with relaxed alertness, while caffeine blocks adenosine receptors to increase arousal — the combination has been shown in multiple human trials to improve sustained attention and reaction time more than either alone.

L-tyrosine is a precursor to dopamine and norepinephrine, and caffeine triggers their release; combining them can modestly improve cognitive performance under stress, fatigue, or sleep deprivation. The synergy is generally well tolerated, though it can mildly amplify caffeine's stimulant effects.